Karuna looks past schizophrenia with $68M series B
By Paul Bonanos, Assistant Editor | Mar 18, 2019 | 2:06 PM GMT
Editor's Note: This article was updated on Mar 19, 2019 at 8:05 PM GMT
Karuna intends to execute on its broader ambitions for lead program KarXT xanomeline/trospium chloride beyond schizophrenia, including development in at least two new indications, after raising $68 million in series B funding.
Read the full 333 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD